MDM2 SNP309 is associated with endometrial cancer susceptibility: A meta-analysis

Human Cell

Volumn 24, Issue 2, 2011, Pages 57-64

  Li, Yan ^a   Zhao, Hongjin ^b   Sun, Li ^c   Huang, Linjuan ^a   Yang, Qifeng ^a   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Endometrial cancer; MDM2; Meta analysis; Single nucleotide polymorphism 309

Indexed keywords

PROTEIN MDM2;

CANCER RISK; CANCER SUSCEPTIBILITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK;

EID: 79958028622     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-011-0013-4     Document Type: Review

References (43)

1. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. Mayo Clin Proc. 2008; 83(1): 97-112.
2. Olson SH, Bandera EV, Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol. 2007; 165(3): 235-45.
3. Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR, Atash-Afza A. Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet Cytogenet. 2010; 196(2): 167-70.
4. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA. 2003; 100(10): 5908-13.
5. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992; 358(6381): 80-3.
6. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005; 5(1): 27-41.
7. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26(15): 3453-9.
8. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002; 12(1): 53-9.
9. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5): 591-602.
10. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005; 65(13): 5481-4.
11. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006; 66(10): 5104-10.
12. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer. 2006; 119(3): 718-21.
13. Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res. 2007; 13(11): 3215-20.
14. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630): 296-9.
15. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 2006; 98(4): 285-8.
16. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis. 2008; 29(4): 754-61.
17. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, et al. The MDM2 promoter polymorphism SNP309T-> G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet. 2005; 42(9): 694-8.
18. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006; 43(6): 531-3.
19. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005; 65(20): 9582-7.
20. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol. 2009; 113(1): 109-14.
21. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008; 17(4): 983-6.
22. Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 2009; 22(4): 101-6.
23. Ueda M, Yamamoto M, Nunobiki O, Toji E, Sato N, Izuma S, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell. 2009; 22(2): 49-54.
24. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol. 2007; 104(3): 660-4.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4): 719-48.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-60.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-88.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-34.
29. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001; 291(5507): 1304-51.
30. Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996; 16(5): 2445-52.
31. Cheah PL, Looi LM. p53: an overview of over two decades of study. Malays J Path. 2001; 23(1): 9-16.
32. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630): 299-303.
33. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005; 24(17): 2899-908.
34. Bouska A, Eischen CM. Mdm2 affects genome stability independent of p53. Cancer Res. 2009; 69(5): 1697-701.
35. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005; 280(29): 26776-87.
36. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA. 2005; 102(45): 16297-302.
37. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 2007; 67(19): 9584-90.
38. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res. 1995; 1(1): 71-80.
39. Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 2003; 63(10): 2616-23.
40. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, et al. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996; 37(2): 179-88.
41. Okumura N, Saji S, Eguchi H, Nakashima S, Saji S, Hayashi S. Distinct promoter usage of mdm2 gene in human breast cancer. Oncol Rep. 2002; 9(3): 557-63.
42. Schultz JR, Petz LN, Nardulli AM. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem. 2005; 280(1): 347-54.
43. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001; 62: 231-52.